Art. 1 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2022cited 16×

The purpose of this Regulation is to lay down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human use and to establish a European Medicines Agency (‘the Agency’) which shall carry out the tasks relating to medicinal products for human use and veterinary medicinal products that are laid down in this Regulation and other relevant Union legislation.

The provisions of this Regulation shall not affect the powers of Member States' authorities as regards setting the prices of medicinal products or their inclusion in the scope of the national health system or social security schemes on the basis of health, economic and social conditions. In particular, Member States shall be free to choose from the particulars shown in the marketing authorisation those therapeutic indications and pack sizes which will be covered by their social security bodies.

The 10 that are cited most themselves, of 16.

  • Opinion of Advocate General Sharpston delivered on 31 January 2013. Novartis Pharma GmbH v Apozyt GmbH.Decision

    Article 1 provides: ‘The purpose of this Regulation is to lay down Community procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human … use …’

    31 Jan 2013 · 62011CC0535

  • Regulation (EU) 2019/5Lawamends

  • Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision

    Whereas the rules laid down in the regulations contain a number of provisions that are essentially procedural (see Article 1 of Regulation No 726/2004), the rules laid down in the directive essentially contain substantive provisions …

    15 Sep 2015 · 62012TJ0472

  • Opinion of Advocate General Bobek delivered on 6 October 2021. Italian Republic and Comune di Milano v Council of the European Union and EurDecision

    … 14 november 2018 is gebaseerd op artikel 114 en artikel 168, lid 4, onder c), VWEU en bevat de volgende bepalingen: „Artikel 1 In verordening (EG) nr. 726/2004 wordt het volgende artikel ingevoegd: ,Artikel 71 bis Het bureau heeft zijn …

    6 Oct 2021 · 62019CC0106

  • Arrêt du Tribunal (deuxième chambre) du 15 septembre 2015. Novartis Europharm Ltd contre Commission européenne.Decision

    Whereas the rules laid down in the regulations contain a number of provisions that are essentially procedural (see Article 1 of Regulation No 726/2004), the rules laid down in the directive essentially contain substantive provisions …

    15 Sep 2015 · 62013TJ0067

  • Opinion of Advocate General Sharpston delivered on 22 April 2010. European Commission v Republic of Lithuania.Decision

    In short, the Regulation Rules contain a number of provisions that are essentially procedural (see Article 1 of the Regulation). In contrast, the Directive Rules, although they make certain procedural references to decentralised …

    22 Apr 2010 · 62008CC0350

  • Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision

    It should be noted in that regard that, under Article 168(7) TFEU, the organisation and management of health services and the allocation of the resources assigned to them are the responsibility of the Member States. Article 4(3) of …

    25 Jul 2018 · 62017CC0029

  • Besluit diergeneesmiddelen1.1Law

    … – buitenverpakking: verpakking waarin de primaire verpakking is geplaatst; – Bureau: bureau, bedoeld in artikel 1 van Verordening (EG) nr. 726/2004; – bijsluiter: informatieblad voor de gebruiker dat het geneesmiddel vergezelt bij de …

  • GmS-OGB, Beschluss vom 22. August 2012 - GmS-OGB 1/10Decision

    … Eine Art. 4 Abs. 3 der Richtlinie 2001/83/EG inhaltsgleiche Regelung sieht Art. 1 Abs. 2 Satz 1 der Verordnung (EG) Nr. 726/2004 vom 31. März 2004 zur Festlegung von Gemeinschaftsverfahren für die Genehmigung und Überwachung von Human …

    22 Aug 2012 · KORE300212013

  • Judgment of the Court (Fourth Chamber) of 14 March 2024. Debregeas et associés Pharma (D & A Pharma) v European Commission and European MediDecision

    The first paragraph of Article 1 of that regulation provides: ‘The purpose of this Regulation is to lay down Union procedures for the authorisation, supervision and pharmacovigilance of medicinal products for human use and to establish …

    14 Mar 2024 · 62022CJ0291